Press Releases

Sign up for Email Alerts Press Release RSS

01/15/2020
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
01/10/2020
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
Term:R&D News
Language:English
01/09/2020
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Term:Corporate/Financial News
Language:English
01/07/2020
Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy
Term:Corporate/Financial News
Language:English
01/06/2020
Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference
Term:Corporate/Financial News
Language:English
01/02/2020
Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
Term:Corporate/Financial News
Language:English
12/20/2019
Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
Term:Corporate/Financial News
Language:English
12/19/2019
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020
Term:Corporate/Financial News
Language:English
12/18/2019
Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
Term:Corporate/Financial News
Language:English
12/13/2019
Bristol-Myers Squibb Announces Leadership Changes
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm